Insider Trades84 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | Buy | EXAS | Sarah Condella | EVP, Human Resources | 5,813 | $37.40 | $20.0B | -0.07% | +170.30% | $217.4K | +0.76% | — | — |
| Feb 27, 2026 | Sell | EXAS | Kevin T Conroy | President and CEO | 32,007 | $103.25 | $20.0B | -0.07% | +170.30% | $3.3M | -0.81% | — | — |
| Feb 25, 2026 | Sell | EXAS | Kevin T Conroy | President and CEO | 6,196 | $103.45 | $20.0B | -0.07% | +170.30% | $641.0K | -0.44% | — | — |
| Dec 23, 2025 | Sell | EXAS | Aaron Bloomer | EVP, Chief Financial Officer | 27,954 | $101.82 | $20.0B | -0.07% | +170.30% | $2.8M | -24.04% | — | — |
| Dec 23, 2025 | Sell | EXAS | Sarah Condella | EVP, Human Resources | 41,938 | $101.82 | $20.0B | -0.07% | +170.30% | $4.3M | -6.27% | — | — |
| Dec 23, 2025 | Sell | EXAS | James Herriott | SVP, General Counsel & Sec | 49,870 | $101.82 | $20.0B | -0.07% | +170.30% | $5.1M | -13.85% | — | — |
| Dec 23, 2025 | Sell | EXAS | Jacob A Orville | EVP, GM, Screening | 68,437 | $101.82 | $20.0B | -0.07% | +170.30% | $7.0M | -12.26% | — | — |
| Dec 23, 2025 | Sell | EXAS | Brian Baranick | EVP, GM, Precision Oncology | 84,097 | $101.78 | $20.0B | -0.07% | +170.30% | $8.6M | -15.15% | — | — |
| Dec 23, 2025 | Sell | EXAS | Kevin T Conroy | President and CEO | 335,549 | $101.82 | $20.0B | -0.07% | +170.30% | $34.2M | -9.28% | — | — |
| Nov 19, 2025 | Sell | EXAS | James Herriott | SVP, General Counsel & Sec | 1,000 | $70.00 | $20.0B | -0.07% | +170.30% | $70.0K | -7.95% | — | — |
| Nov 19, 2025 | Sell | EXAS | Jacob A Orville | EVP, GM, Screening | 5,000 | $75.00 | $20.0B | -0.07% | +170.30% | $375.0K | -17.71% | — | — |
| Nov 4, 2025 | Sell | EXAS | James Herriott | SVP, General Counsel & Sec | 1,500 | $70.08 | $20.0B | -0.07% | +170.30% | $105.1K | -10.65% | — | — |
| Nov 4, 2025 | Sell | EXAS | Brian Baranick | EVP, GM, Precision Oncology | 2,858 | $70.08 | $20.0B | -0.07% | +170.30% | $200.3K | -11.33% | — | — |
| Oct 9, 2025 | Sell | EXAS | James Herriott | SVP, General Counsel & Sec | 1,500 | $60.00 | $20.0B | -0.07% | +170.30% | $90.0K | -9.62% | — | — |
| Aug 5, 2025 | Sell | EXAS | Jacob A Orville | EVP, GM, Screening | 2,515 | $46.83 | $20.0B | -0.07% | +170.30% | $117.8K | -5.37% | — | — |
| Aug 5, 2025 | Sell | EXAS | Brian Baranick | EVP, GM, Precision Oncology | 2,717 | $46.83 | $20.0B | -0.07% | +170.30% | $127.2K | -6.18% | — | — |
| Apr 30, 2025 | Buy | EXAS | James Herriott | SVP, General Counsel & Sec | 363 | $38.26 | $20.0B | -0.07% | +170.30% | $13.9K | +1.61% | — | — |
| Apr 15, 2025 | Sell | EXAS | Aaron Bloomer | EVP, Chief Financial Officer | 10,837 | $44.25 | $20.0B | -0.07% | +170.30% | $479.5K | -15.57% | — | — |
| Mar 7, 2025 | Buy | EXAS | Kevin T Conroy | President and CEO | 115,652 | $32.82 | $20.0B | -0.07% | +170.30% | $3.8M | +0.76% | — | — |
| Feb 28, 2025 | Sell | EXAS | James Herriott | SVP, General Counsel & Sec | 2,006 | $47.82 | $20.0B | -0.07% | +170.30% | $95.9K | -4.77% | — | — |
| Feb 28, 2025 | Sell | EXAS | Sarah Condella | EVP, Human Resources | 4,693 | $37.07 | $20.0B | -0.07% | +170.30% | $174.0K | -1.75% | — | — |
| Feb 28, 2025 | Sell | EXAS | Jacob A Orville | EVP, GM, Screening | 4,547 | $47.82 | $20.0B | -0.07% | +170.30% | $217.4K | -5.90% | — | — |
| Feb 28, 2025 | Sell | EXAS | Brian Baranick | EVP, GM, Precision Oncology | 4,913 | $47.82 | $20.0B | -0.07% | +170.30% | $234.9K | -6.83% | — | — |
| Feb 28, 2025 | Sell | EXAS | Kevin T Conroy | President and CEO | 18,947 | $47.82 | $20.0B | -0.07% | +170.30% | $906.0K | -0.80% | — | — |
| Feb 25, 2025 | Sell | EXAS | James Herriott | SVP, General Counsel & Sec | 775 | $51.28 | $20.0B | -0.07% | +170.30% | $39.7K | -2.65% | — | — |
| Feb 25, 2025 | Sell | EXAS | Jacob A Orville | EVP, GM, Screening | 1,859 | $51.28 | $20.0B | -0.07% | +170.30% | $95.3K | -3.39% | — | — |
| Feb 25, 2025 | Sell | EXAS | Sarah Condella | EVP, Human Resources | 1,859 | $51.28 | $20.0B | -0.07% | +170.30% | $95.3K | -1.72% | — | — |
| Feb 25, 2025 | Sell | EXAS | Brian Baranick | EVP, GM, Precision Oncology | 2,008 | $51.28 | $20.0B | -0.07% | +170.30% | $103.0K | -3.82% | — | — |
| Feb 25, 2025 | Sell | EXAS | Kevin T Conroy | President and CEO | 6,195 | $51.28 | $20.0B | -0.07% | +170.30% | $317.7K | -0.50% | — | — |
| Feb 19, 2025 | Sell | EXAS | James Herriott | SVP, General Counsel & Sec | 1,964 | $50.29 | $20.0B | -0.07% | +170.30% | $98.8K | -8.06% | — | — |
| Feb 19, 2025 | Sell | EXAS | Jacob A Orville | EVP, GM, Screening | 3,311 | $50.20 | $20.0B | -0.07% | +170.30% | $166.2K | -8.93% | — | — |
| Feb 19, 2025 | Sell | EXAS | Sarah Condella | EVP, Human Resources | 3,321 | $50.20 | $20.0B | -0.07% | +170.30% | $166.7K | -2.16% | — | — |
| Feb 19, 2025 | Sell | EXAS | Brian Baranick | EVP, GM, Precision Oncology | 3,405 | $50.24 | $20.0B | -0.07% | +170.30% | $171.1K | -10.38% | — | — |
| Feb 19, 2025 | Sell | EXAS | Kevin T Conroy | President and CEO | 24,411 | $50.37 | $20.0B | -0.07% | +170.30% | $1.2M | -1.10% | — | — |
| Nov 13, 2024 | Buy | EXAS | Kevin T Conroy | President and CEO | 19,500 | $51.35 | $20.0B | -0.07% | +170.30% | $1.0M | +1.85% | — | — |
| Oct 8, 2024 | Sell | EXAS | Brian Baranick | EVP, GM, Precision Oncology | 929 | $70.00 | $20.0B | -0.07% | +170.30% | $65.0K | -6.79% | — | — |
| Sep 18, 2024 | Sell | EXAS | Brian Baranick | EVP, GM, Precision Oncology | 929 | $70.00 | $20.0B | -0.07% | +170.30% | $65.0K | -6.36% | — | — |
| Aug 5, 2024 | Sell | EXAS | Brian Baranick | EVP, GM, Precision Oncology | 1,375 | $55.77 | $20.0B | -0.07% | +170.30% | $76.7K | -3.68% | — | — |
| May 1, 2024 | Sell | EXAS | Jacob A Orville | General Manager, Screening | 102 | $60.15 | $20.0B | -0.07% | +170.30% | $6.1K | -0.70% | — | — |
| May 1, 2024 | Sell | EXAS | Brian Baranick | EVP, GM., Precision Oncology | 110 | $60.15 | $20.0B | -0.07% | +170.30% | $6.6K | -0.82% | — | — |
| Apr 30, 2024 | Buy | EXAS | James Herriott | SVP, General Counsel & Sec | 738 | $31.24 | $20.0B | -0.07% | +170.30% | $23.1K | +3.55% | — | — |
| Apr 30, 2024 | Buy | EXAS | Sarah Condella | EVP, Human Resources | 810 | $33.81 | $20.0B | -0.07% | +170.30% | $27.4K | +0.42% | — | — |
| Apr 30, 2024 | Buy | EXAS | Jeffrey Thomas Elliott | Chief Financial Officer | 843 | $34.88 | $20.0B | -0.07% | +170.30% | $29.4K | +2.47% | — | — |
| Apr 30, 2024 | Buy | EXAS | Everett Cunningham | Chief Commercial Officer | 844 | $34.88 | $20.0B | -0.07% | +170.30% | $29.4K | +0.61% | — | — |
| Apr 30, 2024 | Sell | EXAS | Kevin T Conroy | President and CEO | 1,863 | $48.70 | $20.0B | -0.07% | +170.30% | $90.7K | -0.02% | — | — |
| Apr 2, 2024 | Sell | EXAS | Brian Baranick | EVP, GM., Precision Oncology | 924 | $79.43 | $20.0B | -0.07% | +170.30% | $73.4K | -6.56% | — | — |
| Apr 1, 2024 | Sell | EXAS | Sarah Condella | EVP, Human Resources | 2,000 | $70.00 | $20.0B | -0.07% | +170.30% | $140.0K | -2.71% | — | — |
| Mar 28, 2024 | Sell | EXAS | Sarah Condella | EVP, Human Resources | 2,000 | $70.00 | $20.0B | -0.07% | +170.30% | $140.0K | -2.64% | — | — |
| Mar 1, 2024 | Sell | EXAS | James Herriott | General Counsel | 862 | $59.32 | $20.0B | -0.07% | +170.30% | $51.1K | -5.51% | — | — |
| Mar 1, 2024 | Sell | EXAS | Sarah Condella | EVP, Human Resources | 1,724 | $59.32 | $20.0B | -0.07% | +170.30% | $102.3K | -1.94% | — | — |
| Mar 1, 2024 | Sell | EXAS | Jacob A Orville | General Manager, Screening | 2,154 | $59.32 | $20.0B | -0.07% | +170.30% | $127.8K | -7.03% | — | — |
| Mar 1, 2024 | Sell | EXAS | Brian Baranick | Gen. Mgr., Precision Oncology | 2,323 | $59.32 | $20.0B | -0.07% | +170.30% | $137.8K | -7.59% | — | — |
| Mar 1, 2024 | Sell | EXAS | Everett Cunningham | Chief Commercial Officer | 2,412 | $59.32 | $20.0B | -0.07% | +170.30% | $143.1K | -3.74% | — | — |
| Mar 1, 2024 | Sell | EXAS | Jeffrey Thomas Elliott | Chief Financial Officer | 2,412 | $59.32 | $20.0B | -0.07% | +170.30% | $143.1K | -8.25% | — | — |
| Mar 1, 2024 | Sell | EXAS | Kevin T Conroy | President and CEO | 8,271 | $59.32 | $20.0B | -0.07% | +170.30% | $490.6K | -0.61% | — | — |
| Feb 27, 2024 | Sell | EXAS | James Herriott | General Counsel | 784 | $56.89 | $20.0B | -0.07% | +170.30% | $44.6K | -3.62% | — | — |
| Feb 27, 2024 | Sell | EXAS | Jacob A Orville | General Manager, Screening | 1,879 | $56.89 | $20.0B | -0.07% | +170.30% | $106.9K | -4.55% | — | — |
| Feb 27, 2024 | Sell | EXAS | Sarah Condella | EVP, Human Resources | 1,880 | $56.89 | $20.0B | -0.07% | +170.30% | $107.0K | -1.89% | — | — |
| Feb 27, 2024 | Sell | EXAS | Brian Baranick | Gen. Mgr., Precision Oncology | 2,027 | $56.89 | $20.0B | -0.07% | +170.30% | $115.3K | -4.89% | — | — |
| Feb 27, 2024 | Sell | EXAS | Jeffrey Thomas Elliott | Chief Financial Officer | 2,710 | $56.89 | $20.0B | -0.07% | +170.30% | $154.2K | -10.07% | — | — |
| Feb 27, 2024 | Sell | EXAS | Everett Cunningham | Chief Commercial Officer | 3,648 | $56.89 | $20.0B | -0.07% | +170.30% | $207.5K | -3.88% | — | — |
| Feb 27, 2024 | Sell | EXAS | Kevin T Conroy | President and CEO | 6,263 | $56.89 | $20.0B | -0.07% | +170.30% | $356.3K | -0.44% | — | — |
| Feb 23, 2024 | Sell | EXAS | Sarah Condella | EVP, Human Resources | 1,021 | $59.72 | $20.0B | -0.07% | +170.30% | $61.0K | -1.40% | — | — |
| Feb 23, 2024 | Buy | EXAS | Kevin T Conroy | President and CEO | 164,397 | $30.28 | $20.0B | -0.07% | +170.30% | $5.0M | +1.60% | — | — |
| Feb 22, 2024 | Sell | EXAS | James Herriott | General Counsel | 291 | $59.78 | $20.0B | -0.07% | +170.30% | $17.4K | -3.87% | — | — |
| Feb 22, 2024 | Sell | EXAS | Sarah Condella | EVP, Human Resources | 1,013 | $59.78 | $20.0B | -0.07% | +170.30% | $60.6K | -1.37% | — | — |
| Feb 22, 2024 | Sell | EXAS | Jacob A Orville | General Manager, Screening | 1,013 | $59.78 | $20.0B | -0.07% | +170.30% | $60.6K | -9.47% | — | — |
| Feb 22, 2024 | Sell | EXAS | Brian Baranick | Gen. Mgr., Precision Oncology | 1,093 | $59.78 | $20.0B | -0.07% | +170.30% | $65.3K | -10.06% | — | — |
| Feb 22, 2024 | Sell | EXAS | Everett Cunningham | Chief Commercial Officer | 1,350 | $59.78 | $20.0B | -0.07% | +170.30% | $80.7K | -3.32% | — | — |
| Feb 22, 2024 | Sell | EXAS | Jeffrey Thomas Elliott | Chief Financial Officer | 1,351 | $59.78 | $20.0B | -0.07% | +170.30% | $80.8K | -21.06% | — | — |
| Feb 22, 2024 | Sell | EXAS | Kevin T Conroy | President and CEO | 11,565 | $59.78 | $20.0B | -0.07% | +170.30% | $691.4K | -0.92% | — | — |
| Feb 21, 2024 | Sell | EXAS | James Herriott | General Counsel | 415 | $61.50 | $20.0B | -0.07% | +170.30% | $25.5K | -5.64% | — | — |
| Feb 21, 2024 | Sell | EXAS | Brian Baranick | Gen. Mgr., Precision Oncology | 895 | $61.50 | $20.0B | -0.07% | +170.30% | $55.0K | -9.21% | — | — |
| Feb 21, 2024 | Sell | EXAS | Jacob A Orville | General Manager, Screening | 1,078 | $61.50 | $20.0B | -0.07% | +170.30% | $66.3K | -11.07% | — | — |
| Feb 21, 2024 | Sell | EXAS | Sarah Condella | EVP, Human Resources | 1,079 | $61.50 | $20.0B | -0.07% | +170.30% | $66.4K | -1.48% | — | — |
| Feb 21, 2024 | Sell | EXAS | Jeffrey Thomas Elliott | Chief Financial Officer | 1,493 | $61.50 | $20.0B | -0.07% | +170.30% | $91.8K | -28.73% | — | — |
| Feb 21, 2024 | Sell | EXAS | Kevin T Conroy | President and CEO | 4,975 | $61.50 | $20.0B | -0.07% | +170.30% | $306.0K | -0.40% | — | — |
| Feb 15, 2024 | Sell | EXAS | Sarah Condella | EVP, Human Resources | 965 | $61.43 | $20.0B | -0.07% | +170.30% | $59.3K | -1.35% | — | — |
| Feb 15, 2024 | Sell | EXAS | Jacob A Orville | General Manager, Screening | 966 | $61.43 | $20.0B | -0.07% | +170.30% | $59.3K | -11.43% | — | — |
| Feb 15, 2024 | Sell | EXAS | Jeffrey Thomas Elliott | Chief Financial Officer | 1,888 | $61.43 | $20.0B | -0.07% | +170.30% | $116.0K | -47.53% | — | — |
| Jan 2, 2024 | Sell | EXAS | Brian Baranick | Gen. Mgr., Precision Oncology | 879 | $73.50 | $20.0B | -0.07% | +170.30% | $64.6K | -9.91% | — | — |
| Jan 2, 2024 | Sell | EXAS | Sarah Condella | EVP, Human Resources | 2,000 | $73.50 | $20.0B | -0.07% | +170.30% | $147.0K | -2.80% | — | — |
| Dec 14, 2023 | Sell | EXAS | Sarah Condella | EVP, Human Resources | 2,000 | $70.00 | $20.0B | -0.07% | +170.30% | $140.0K | -2.72% | — | — |
| Oct 31, 2023 | Sell | EXAS | James Herriott | General Counsel | 489 | $57.06 | $20.0B | -0.07% | +170.30% | $27.9K | -2.74% | — | — |